The HIV+Hepatitis Policy Institute (HIV+Hep) and American Autoimmune Related Diseases Association (AARDA), along with 38 other patient organizations, filed comments earlier this week with the U.S. Department of Health and Human Services (HHS) addressed to Secretary Xavier Becerra that urge HHS to improve the affordability of prescription drugs for patients in the private insurance market through Standard Benefit Plans.
Biden administration passes on protecting patient affordability of medications
“We are deeply disappointed that CMS passed on addressing the issue of copay assistance for prescription drugs and requiring insurers and pharmacy benefit managers (PBMs) to count assistance towards patient out-of-pocket cost-sharing and deductibles,” commented Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.
Trump Administration fails to protect patient affordability of medications: Biden Administration must step in to improve affordability
Washington DC… Today, the Trump administration rushed out the partial release of the rules that govern how private health plans must operate in 2022 and in doing so…
Trump Administration temporarily backs off from proposal that would endanger patient copay assistance
Washington DC… In a victory for patients’ ability to afford prescription drugs, the Trump administration has delayed for two years implementation of a provision included in a proposed…
Trump Administration medicaid proposal endangers patient assistance programs in private insurance market
Washington DC…In a setback to patients’ ability to afford prescription drugs, the Trump administration has again attacked the use of drug manufacturer copay assistance for prescription…